In vitro activity of telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood:: Antimicrobial susceptibility patterns in different groups of species

被引：20

作者：

Rodríguez-Avial, M ^{[1
]}

Rodríguez-Avial, C ^{[1
]}

Culebras, E ^{[1
]}

Picazo, JJ ^{[1
]}

机构：

[1] Hosp Clin San Carlos, Microbiol Serv, Madrid 28040, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 02期

关键词：

D O I：

10.1128/AAC.49.2.820-823.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activities of penicillin, erythromycin, clindamycin, and telithromycin were determined against 155 viridans group streptococci (VGS) and 18 Streptococcus bovis blood isolates. Heterogeneity in the susceptibility patterns and macrolide resistance phenotypes and genotypes in the different groups of VGS was detected. We found seven telithromycin-resistant S. bovis isolates all harboring the erm(B) gene.

引用

页码：820 / 823

页数：4

共 23 条

[1] In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group streptococci isolated from blood of neutropenic patients with cancer [J].

Alcaide, F ;

Benítez, MA ;

Carratalà, J ;

Gudiol, F ;

Liñares, J ;

Martín, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :624-626

[2]

[Anonymous], 2004, M100S14 NAT COMM CLI

[3] High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples:: a reservoir of mef genes in commensal bacteria [J].

Aracil, B ;

Miñambres, M ;

Oteo, J ;

Torres, C ;

Gómez-Garcés, JL ;

Alós, JI .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :592-594

[4] Incidence of mefA and mefE genes in viridans group streptococci [J].

Arpin, C ;

Canron, MH ;

Maugein, J ;

Quentin, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2335-2336

[5] CLASSIFICATION AND IDENTIFICATION OF THE VIRIDANS STREPTOCOCCI [J].

COYKENDALL, AL .

CLINICAL MICROBIOLOGY REVIEWS, 1989, 2 (03) :315-328

[6] In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada [J].

de Azavedo, JCS ;

Trpeski, L ;

Pong-Porter, S ;

Matsumura, S ;

Low, DE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2299-2301

[7] Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America [J].

Diekema, DJ ;

Beach, ML ;

Pfaller, MA ;

Jones, RN .

CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (03) :152-157

[8] Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States [J].

Doern, GV ;

Ferraro, MJ ;

Brueggemann, AB ;

Ruoff, KL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :891-894

[9] Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000 [J].

Gershon, AS ;

de Azavedo, JCS ;

McGeer, A ;

Ostrowska, KI ;

Church, D ;

Hoban, DJ ;

Harding, GKM ;

Weiss, K ;

Abbott, L ;

Smaill, F ;

Gourdeau, M ;

Murray, G ;

Low, DE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1553-1556

[10] Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S-milleri") group [J].

Jacobs, JA ;

van Baar, GJ ;

London, NHHJ ;

Tjhie, JHT ;

Schouls, LM ;

Stobberingh, EE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2375-2377

← 1 2 3 →